Bandingkan Harga & Kinerja Bank China Construction Bank Indonesia Tbk. (MCOR) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Bank China Construction Bank Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: Bank China Construction Bank Indonesia Tbk. diperdagangkan di Rp69 (kapitalisasi pasar 2,59 T, volume 24 jam 1,91 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Bank China Construction Bank Indonesia Tbk. jauh lebih besar — sekitar 24,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| MCOR | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 2,59 T | 104,4 M |
Volume | 1,91 jt | — |
Lot | 19,07 rb | — |
Perputaran | 132,14 jt | — |
Harga Rata-rata | 69,29 | — |
Nilai Transaksi | 132,14 jt | — |
Harga Ekuilibrium Indikatif | 69 | — |
Volume Ekuilibrium Indikatif | 113 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Bank China Construction Bank Indonesia Tbk.
PT Bank Multicor (Bank) was established under its original name of PT Multinational Finance Corporation base on notarial deed No.4 of Mr Bagijo, S.H, dated on Apr 2, 1974. The Company’s articles of association has been amended several times, most recently by notarial deed No. 143 of Eliwati Tjitra, S.H., dated Mar 21, 2007, concerning among others, the change in the Company’s name, Anggaran Dasar and public offering. The Bank's name was changed to PT Bank Windu Kentjana International Tbk.
Selengkapnya di halaman MCOR →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
